http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#Head
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#assertion
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#provenance
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#pubinfo
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#assertion
http://purl.obolibrary.org/obo/DOID_8504
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_8504
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB01112
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#association
http://www.w3.org/2000/01/rdf-schema#label
note cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are not substitutable on a milligram per milligram basis see clinical pharmacology cefuroxime axetil for oral suspension is indicated for the treatment of pediatric patients 3 months to 12 years of age with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below the safety and effectiveness of cefuroxime axetil for oral suspension in the treatment of infections other than those specifically listed below have not been established either by adequate and well controlled trials or by pharmacokinetic data with which to determine an effective and safe dosing regimen pharyngitis tonsillitis note acute bacterial otitis media impetigo to reduce the development of drug resistant bacteria and maintain the effectiveness of cefuroxime axetil for oral suspension and other antibacterial drugs cefuroxime axetil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB01112
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#provenance
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#pubinfo
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#sig
http://purl.org/nanopub/x/hasSignature
Em/cR/09W5oCB5MZE1Ra5WHajEfi2Mco0zissgbQv5d+ArrumGMQhYfPz8FEYwAlqFJKBkJPUT7FDtWskE+0zE9NUK1pWonNo+E/URksmltqiX7YwV89mVrgrv1zCAR2GVFes2/lRNJC9lUACtVkCdnWJW93TMavOLOaJNeAbZk=
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE
http://purl.org/dc/terms/created
2021-06-13T16:35:11.551+02:00
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs